Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2731061 | 0.86 | SMN1; SMN2 (0.44) | TP53KMT2AUSP2ALDH1A1MAPT | |
| SCHEMBL15825922 | 0.76 | TP53 (0.49) | TP53KMT2AUSP2KCNJ1KDM4E | |
| SCHEMBL15211430 | 0.73 | ESR1 (0.42) | KMT2AALDH1A1MAPTMEN1HPGD | |
| SCHEMBL1679129 | 0.72 | MAP3K14 (0.44) | ALDH1A1HPGDKDM4EHTTL3MBTL1 | |
| SCHEMBL30016781 | 0.72 | FFAR1 (0.39) | TP53ALDH1A1MAPTHTT | |
| SCHEMBL21557569 | 0.72 | FFAR1 (0.39) | TP53ALDH1A1MAPTHTT | |
| SCHEMBL31432485 | 0.72 | MTNR1A (0.47) | TP53USP2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2729054 | 0.72 | GAA (0.36) | ALDH1A1KDM4E | |
| SCHEMBL31661184 | 0.70 | MAPT (0.47) | KMT2AALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL13576751 | 0.69 | GLS (0.46) | KMT2AALDH1A1MAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | TP53 4844/4885KMT2A 1177/4885USP2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.